STOCK TITAN

Attovia Therapeutics: venBio reports about 9.2% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

For Attovia Therapeutics, Inc. (ATTO), venBio Global Strategic Fund IV, L.P. and venBio Global Strategic GP IV, LLC each may be deemed to beneficially own 4,181,366 common shares, approximately 9.2%, as of September 30, 2026. Each has shared voting and dispositive power over 4,181,366 shares. The 9.2% figure is based on 45,683,050 shares outstanding as of that date. Aaron Royston, Corey Goodman, and Richard Gaster, members of General Partner IV, disclaim beneficial ownership of the reported shares.

Beneficially owned shares 4,181,366 shares Each reporting person; as of September 30, 2026
Ownership percentage Approximately 9.2% Each reporting person; based on shares outstanding as of September 30, 2026
Shares outstanding 45,683,050 shares As of September 30, 2026; basis for the reported ownership percentage
beneficial ownership technical
"may be deemed to beneficially own 4,181,366 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power technical
"shared voting power over 4,181,366 shares"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"shared dispositive power over 4,181,366 shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ATTO shares does venBio report beneficially owning?

venBio Global Strategic Fund IV, L.P. and venBio Global Strategic GP IV, LLC each may be deemed to beneficially own 4,181,366 ATTO common shares, approximately 9.2%, as of September 30, 2026. The percentage is based on 45,683,050 shares outstanding on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





04987L102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



venBio Global Strategic Fund IV, L.P.
Signature:/s/ David Pezeshki
Name/Title:David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members of the General Partner
Date:11/16/2026
venBio Global Strategic GP IV, LLC
Signature:/s/ David Pezeshki
Name/Title:David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members
Date:11/16/2026

Comments accompanying signature: This Schedule 13G was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, copies of which are attached as Exhibit 2 and Exhibit 3 to the Schedule 13G.
Exhibit Information

Exhibit 1: Joint Filing Agreement Exhibit 2: Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended Exhibit 3: Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended

Keep reading